Body Care

Business

Stryker Caps Strong 2025 with Record Robotics Growth, Eyes Further Expansion Amid Tariff Headwinds

The medical technology giant reported double-digit organic sales growth and robust profitability for 2025, driven by record installations of its Mako surgical robots. While projecting continued strength for 2026, management acknowledged incremental tariff pressures but expressed confidence in the company's ability to sustain margin expansion.

Jan 30, 2026

Business

Schneider National Navigates Tough Q4 as Freight Demand Falters, Eyes Supply-Driven Recovery

Schneider National's Q4 2025 earnings fell short of expectations, pressured by a sharp late-year drop in freight demand and severe weather. While acknowledging near-term challenges, executives pointed to early signs of market normalization and detailed strategic cost actions aimed at positioning the carrier for an eventual upcycle.

Jan 30, 2026

Business

UBS Initiates Coverage on Zai Lab with Buy Rating, Touts Global Ambitions Beyond China

Swiss banking giant UBS has initiated coverage on Zai Lab Limited (NASDAQ: ZLAB) with a bullish 'Buy' rating and a $35 price target, highlighting the biopharma firm's strategic pivot from a China-focused player to a burgeoning global innovation platform with a promising proprietary pipeline.

Jan 30, 2026

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Jan 30, 2026

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.

Jan 30, 2026

World

Private Equity and Sovereign Wealth Funds Profit from UK's Special Educational Needs Crisis

As demand for specialist education soars, private investors—from Abu Dhabi to private equity firms—are capitalizing on a strained system, drawing criticism for extracting profits from vulnerable children and cash-strapped councils.

Jan 30, 2026

Business

China Approves Sciwind's Diabetes Drug Xianyida, Intensifying GLP-1 Market Competition

Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.

Jan 30, 2026

Business

ResMed Posts Strong Q2 Growth, Eyes GLP-1 Tailwind and AI-Driven Innovation

ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.

Jan 30, 2026

Business

Fractyl Health Charts Path for Revita as Potential Solution to Post-GLP-1 Weight Regain

Fractyl Health's Revita procedure shows promise in maintaining weight after stopping GLP-1 drugs, with new six-month data prompting the company to seek a streamlined FDA pathway. A packed 2026 roadmap aims for a U.S. submission, but financial pressures loom.

Jan 30, 2026

Business

AI Bubble Fears Loom Over 2026 Markets, But This S&P 500 ETF Remains a Bedrock Strategy

As trillion-dollar AI infrastructure spending fuels concerns of a market bubble, long-term investors are questioning whether broad index funds like the Vanguard S&P 500 ETF still offer a safe harbor.

Jan 30, 2026

Business

Gold's Meteoric Rise: Safe Haven or Speculative Frenzy?

Gold prices have surged past $5,500, driven by geopolitical tensions and fiscal fears. Yet, analysts caution that its reputation as a stable store of value may be overstated, pointing to inherent volatility and shifting market dynamics.

Jan 30, 2026

Business

Beyond the Trillion-Dollar Mark: Broadcom's AI-Driven Ascent and the Road Ahead for 2026

Having cemented its status as a trillion-dollar titan on the back of the AI boom, semiconductor leader Broadcom now sets its sights on sustained growth. We analyze the drivers behind its surge and what investors can expect in the coming year.

Jan 30, 2026

Business

Insider Bets Signal Confidence in Select European Growth Stocks Amid Market Uncertainty

As the STOXX Europe 600 stumbles under geopolitical and trade pressures, a focus on companies with significant insider ownership reveals where leadership is putting its own capital on the line. We examine three firms where high insider stakes coincide with robust growth forecasts.

Jan 30, 2026

Business

Bank of America Lifts Target on Xencor Amid Broader Biotech Sector Optimism

Bank of America has raised its price target for clinical-stage biopharma firm Xencor (XNCR), highlighting a cautiously improving landscape for the sector driven by data catalysts, M&A, and capital access.

Jan 30, 2026

Business

Nuvation Bio's Ibtrozi Gains Favor on Strong Launch, Truist Raises Target

Truist Securities has increased its price target for Nuvation Bio, highlighting the promising early commercial traction of its oncology drug Ibtrozi, which is outpacing competitors in the ROS1 inhibitor space.

Jan 30, 2026

Business

TD Cowen Stands By Alphatec (ATEC) With Buy Rating, Sees $20 Target Amid Coverage Shift

Despite a lowered price target following an analyst transition, TD Cowen maintains a bullish stance on Alphatec Holdings, citing undervalued growth drivers including a new regenerative bone graft partnership and a robust long-term revenue outlook.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

Hutchison Port Holdings Trust Sees Efficiency Gains, But Can Its ROCE Momentum Hold?

The Singapore-listed port operator has significantly improved its capital efficiency over five years, rewarding shareholders. Analysts are now weighing whether this trend is sustainable for long-term growth.

Jan 30, 2026

Business

PennyMac Mortgage Investment Trust Posts Strong Q4 Results, Eyes Growth in Non-Agency Market

PennyMac Mortgage Investment Trust (PMT) reported a robust fourth quarter, highlighted by a 13% return on equity and strategic advancements in its securitization business. Executives outlined a confident outlook for 2026, emphasizing disciplined risk management and growth in targeted lending segments.

Jan 30, 2026

Business

Stryker Caps Record Year with Strong Q4, Bullish on 2026 Despite Market Headwinds

The medical technology giant reports double-digit organic sales growth for the fourth consecutive year, driven by its Mako robotic system and strategic leadership shifts, while navigating tariffs and a shifting competitive landscape.

Jan 30, 2026